{"entity":{"id":"nct05194995","kind":"trial","name":"JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation","aka":[],"tldr":"A phase 1/2 trial of Glecirasib, Cetuximab in colorectal cancer, run by Allist Pharmaceuticals, Inc., active and no longer recruiting.","summary":"JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation is a phase 1/2 interventional study registered as NCT05194995 by Allist Pharmaceuticals, Inc., with 48 participants enrolled, started 2022-02-17 and due to reach its primary completion in 2025-04-30. Interventions recorded: JAB-21822, Cetuximab. Conditions listed: Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05194995","url":"https://clinicaltrials.gov/study/NCT05194995"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["glecirasib","cetuximab"],"companies":["allist"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05194995","phase":"1/2","setting":"A Phase Ib/II Trial of JAB-21822 in Combination With Cetuximab in Patients With Advanced Colorectal Cancer, Small Intestine Cancer and Appendiceal Cancer With KRAS G12C Mutation","sponsor":"Allist Pharmaceuticals, Inc.","enrolled":48,"outcomes":[]},"route":"/trials/nct05194995/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"glecirasib","kind":"drug","name":"Glecirasib","route":"/drugs/glecirasib/"}],"company":[{"id":"allist","kind":"company","name":"Shanghai Allist Pharmaceuticals","route":"/companies/allist/"}]}}